SLC35A2 Activators
SLC35A2 Activators are chemical compounds that enhance the functional activity of SLC35A2, a crucial transporter involved in the glycosylation process within the Golgi apparatus. The activity of SLC35A2 is intrinsically linked to the availability and regulation of its substrate; thus, compounds like UDP-Galactose directly enhance SLC35A2's function by increasing the substrate concentration, facilitating more efficient galactosylation. Bisphenol A, through its interaction with estrogen receptors, indirectly augments SLC35A2 by potentially upregulating the expression of genes related to glycosylation, thus possibly increasing SLC35A2's transport capacity. Similarly, Tamoxifen's modulation of estrogenic pathways is speculated to raise the cellular demand for glycosylation, consequently enhancing SLC35A2's activity. Chemical chaperones such as 4-Phenylbutyrate may indirectly elevate SLC35A2 efficiency by promoting the proper folding and function of glycosylation transporters, ensuring their stability and performance.
Brefeldin A, through its disruptive effects on Golgi architecture, may provoke a similar compensatory response, indirectly promoting SLC35A2 activity. These compounds, by targeting various aspects of the glycosylation pathway and cellular stress mechanisms, contribute to the enhanced functional activation of SLC35A2.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisphenol A | 80-05-7 | sc-391751 sc-391751A | 100 mg 10 g | $300.00 $490.00 | 5 | |
Bisphenol A interacts with estrogen receptors and can influence estrogenic signaling. Estrogen has been shown to increase the expression of glycosylation-related genes. As SLC35A2 is directly involved in the glycosylation process by transporting UDP-galactose into the Golgi apparatus, Bisphenol A may enhance the functional capacity of SLC35A2 by upregulating its expression and activity in the glycosylation pathway. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen, known as an estrogen receptor modulator, can lead to alterations in gene expression profiles, including those of glycosylation enzymes and transporters. By modulating estrogenic pathways, Tamoxifen can indirectly enhance the activity of SLC35A2 by increasing the cellular demand for glycosylation, which is dependent on the function of SLC35A2 in transporting nucleotide sugars. | ||||||
UDP-α-D-Galactose disodium salt | 137868-52-1 | sc-286849 sc-286849A sc-286849B | 10 mg 50 mg 1 g | $104.00 $198.00 $2968.00 | 1 | |
UDP-Galactose is the direct substrate of SLC35A2. Increasing the intracellular concentration of UDP-Galactose can enhance the activity of SLC35A2 by providing more substrate for transport into the Golgi, a critical step in glycosylation processes. | ||||||
Sodium phenylbutyrate | 1716-12-7 | sc-200652 sc-200652A sc-200652B sc-200652C sc-200652D | 1 g 10 g 100 g 1 kg 10 kg | $77.00 $166.00 $622.00 $5004.00 $32783.00 | 43 | |
4-Phenylbutyrate acts as a chemical chaperone, which can enhance the proper folding and function of proteins, including glycosylation enzymes and transporters. By promoting proper folding, this compound may indirectly enhance the activity of SLC35A2 by ensuring the stability and efficiency of the protein in its role of transporting UDP-galactose. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi structure, which can lead to a cellular response to enhance the glycosylation machinery to maintain protein processing. This could potentially increase the functional activity of SLC35A2 as the cell compensates for the perturbed Golgi function. | ||||||